Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of acute lymphoblastic leukemia

A technology for acute lymphoblastic leukemia, applied in chemical instruments and methods, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, immunoglobulin, etc., can solve the problem of poor efficacy in relapsed acute lymphoblastic leukemia question

Inactive Publication Date: 2011-10-05
AMGEN RES (MUNICH) GMBH
View PDF7 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the standard risk type (Hoelzer et al., Hematology Am. Standard-risk) patients are potentially placed at unnecessary risk by intensive and long-term treatment, and the efficacy of patients with relapsed acute lymphoblastic leukemia (ALL) is extremely poor, even if a second remission period is achieved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of acute lymphoblastic leukemia
  • Treatment of acute lymphoblastic leukemia
  • Treatment of acute lymphoblastic leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0117] 1. The production, expression and cytotoxic activity of the CD19xCD3 bispecific single chain antibody are described in WO 99 / 54440. The corresponding amino acid and nucleic acid sequences of the CD19xCD3 bispecific single chain antibody are shown in SED ID NO.1 and 2, respectively. The VH and VL regions of the CD3-binding domain of the CD19xCD3 bispecific single-chain antibody are shown in SED ID NO.7-10, respectively, while the VH and VL regions of the CD19-binding domain of the CD19xCD3 bispecific Shown in SED ID NO.3-6. The corresponding CDR regions are shown in SED ID NO.11-22.

[0118] 2. The ongoing Phase I trial in patients with relapsed B-NHL showed that 60 μg / m 2 CD19xCD3 bispecific single chain antibody per day can obtain high response rate. Response duration was up to 12+ months (in several patients). at 15μg / m 2 Bone marrow infiltrating B-NHL cells were removed every day (Bargou et al., Science 2008).

[0119] 3. Based on these results, a phase II dose...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to an adult patient in the need thereof.

Description

technical field [0001] The present invention relates to a method of treating, ameliorating or eliminating acute lymphoblastic leukemia (ALL), the method comprising administering to an adult patient in need thereof a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct. Background technique [0002] Leukemia is a clonal neoplastic proliferation of immature hematopoietic cells characterized by abnormal or blocked differentiation. Leukemic cells accumulate in the bone marrow, eventually replacing most normal blood-forming cells. This leads to bone marrow failure, which results in anemia, bleeding and infection. Leukemic cells circulate into the blood and other tissues throughout the body (DeVita, Hellmann, Rosenberg. Cancer: principles and practice of oncology. Eight edition. Library of Congress Cataloging-in-Publication Data, ISBN 0-781-72387-6). Acute leukemias can be broadly classified as lymphocytic or myeloid leukemias, which are ph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K16/46
CPCC07K16/2809C07K16/468C07K16/2803A61K2039/505A61P35/02C07K2317/31A61K39/39533C07K16/2896C12N15/00
Inventor 格哈德·祖格迈尔伊夫林·德根哈德
Owner AMGEN RES (MUNICH) GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com